Skip to Content

TAK-573-1001: An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 as a Single Agent and in Combination with Pembrolizumab in Adult Patients With Metastatic Solid Tumors


Clinical Trial Details

Principal Investigator(s)
Heidi McKean, MD

Clinical Trial Categories

  • Melanoma
Medical Oncology Research Coordinators at 605-322-3295


  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.